TUDCA Benefits: What the Trials Measured and What They Never Did

Search for TUDCA benefits or a liver cleanse and you land on the same shelf, sold on the same promise: your liver is clogged, and this unclogs it. One product on that shelf even hands you proof you can hold in your hand.

A woman in her forties, whose gallstones had been confirmed on ultrasound before she tried an olive oil and citrus flush, sent the green stones she passed to a laboratory. They had no crystal structure. They were mostly fatty acids, with no cholesterol, bilirubin or calcium. Investigators then made identical objects on a bench from oleic acid, lemon juice and potassium hydroxide. She had made soap, and she still had her gallstones.

I’m Dr. Gurpreet Singh Padda, MD, MBA, MHP. The Chapter 28 video of The Angry Gut, The Liver Flush Is Soap, works through the whole shelf. Here the question is what the human trials behind these bottles measured, and which numbers in your own blood work should decide whether anything works.

A liver cleanse that manufactures its own proof

That is a single case report, but the chemistry does not care how many testimonials disagree.

The cleanse treats bile as sludge to be expelled. Bile is a defense and a signal: it emulsifies fat, carries fat-soluble vitamins in, helps keep bacterial debris out of the blood, and shapes which microbes can live in the bowel. The biology of that signal is covered in why bile acts as a hormone the liver listens to. The practical question is whether anything in a bottle restores it.

TUDCA is not ursodiol, whatever the label implies

Ursodeoxycholic acid, sold as ursodiol, is a prescription drug with a real indication. Tauroursodeoxycholic acid, TUDCA, is its taurine-bound cousin sold as a supplement, largely on the drug’s reputation. So start with what the drug itself does in its home disease, primary biliary cholangitis.

Pooled across trials, deaths ran 45 of 699 on the drug and 46 of 692 without it, a relative risk of 0.97. Death or transplant combined did not change, nor did itch or fatigue. Alkaline phosphatase dropped by 257 U/L. One tissue result did move: worsening of liver stage occurred in 66 of 281 treated patients against 103 of 270 controls, a relative risk of 0.62. Only one of those trials had low risk of bias, though.

None of those patients took TUDCA. An industry borrowed the trials and charges for the resemblance, and nothing on the bottle has to say so.

What TUDCA benefits look like in actual human trials

The metabolic trial enrolled 20 obese adults with a mean body mass index of 37. At 1,750 mg a day for four weeks, insulin sensitivity in liver and muscle rose by about 30%, and fat tissue did not respond. The cellular stress markers the study was designed around did not budge, so the effect was real and the proposed explanation was not.

The neurology trial gave 2 g a day for sixteen weeks to people with progressive multiple sclerosis and analyzed 47 of them, 26 on the supplement and 21 on placebo. Adverse events did not differ. It was absorbed, and immune cells and gut flora shifted. Clinical and fluid biomarker outcomes showed no significant difference.

That is early human evidence, and it is worth acting on: TUDCA gets in, is tolerated, and moves metabolic and immune measures. Neither trial measured a single liver or gut endpoint. If you take it for your liver, you are extrapolating from muscle and lymphocytes.

Name the number before you start the bottle

The most useful trial in this whole file was not about a supplement. Investigators took 100 people with primary biliary cholangitis who were already on ursodiol and still failing an agreed response standard, then added either bezafibrate or placebo for two years while everyone stayed on the original drug.

Complete biochemical response reached 31% with bezafibrate and 0% with placebo. Alkaline phosphatase normalized in 67% against 2%. The add-on had a cost: muscle pain ran 20% against 10%.

The placebo arm stayed on standard treatment for two years and almost nothing normalized; non-response was visible in blood work all along. The lesson for any bile agent, prescription or bottle, is to write down which number should move and by when, then check it. Any change to a prescription runs through your physician.

Milk thistle benefits, once the weak trials come out

A Cochrane review pooled 18 randomized trials and 1,088 patients with alcohol-related or viral liver disease. Liver-related mortality looked like a win across all trials, a relative risk of 0.50 with an interval of 0.29 to 0.88. Restricted to high-quality trials, it became 0.57 with an interval of 0.28 to 1.19. The size held; the certainty did not.

A trial funded by the National Institutes of Health, in 154 people with hepatitis C, found response rates of 4.0% and 3.8% on two high doses against 3.8% on placebo. A 2025 synthesis of 55 studies and 3,545 patients found enzyme drops in fatty liver and viral hepatitis, none in drug-induced or alcohol-related injury, no effect on alkaline phosphatase, and none at a body mass index of 30 or above. Doses under 400 mg did better than larger ones, a backward pattern that usually signals small-study noise rather than biology.

The terrain question nobody has measured

Bile and microbes move together. In 47 people with cirrhosis compared with 14 controls, advanced disease carried the lowest secondary bile acids, the products bacteria make from bile. Ruminococcaceae tracked the deoxycholic to cholic acid ratio at r=0.82. The organisms doing the chemistry rise and fall with its product. It is cross-sectional work, and stool bile acids are a downstream readout, so the census is not the activity.

Under every bottle sits a claim nobody has tested. No herbal, dietary or pharmaceutical agent has been shown to raise measured bile flow in a living human. That trial has not been run for an economic reason as much as a scientific one: the person who needs the answer arrives with metabolic disease, a medication list and a shelf of supplements, and clean cohorts are cheaper to recruit and easier to publish. One trial would change my view: people with measured bile acid malabsorption, a bile agent against placebo, and bile output measured directly.

Before the next bottle

• Write down the marker that should move, such as alkaline phosphatase, bilirubin or liver enzymes, and a date to recheck it.
• Ask whether a supplement was tested in your condition.
• Put the metabolic terrain first. You cannot out-inject a broken metabolism, and a capsule does not out-supplement one.

A fatty liver and a stalled bile supply share one terrain with insulin resistance, which is why the same treatment can work in one body and fail in another. The previous installment, on why the weeds were never the problem, sets up this one, and how to heal a leaky gut once drainage works comes next. Every trial named here, with full numbers and the limits of each, is in the Chapter 28 Deep Dive.

Frequently asked questions

Is TUDCA the same as ursodiol?

No. Ursodiol is ursodeoxycholic acid, a prescription drug. TUDCA is the taurine-conjugated form, sold as a supplement. Most outcome data people quote belong to ursodiol in primary biliary cholangitis, where it moved blood tests but not deaths, itch or fatigue. TUDCA’s own human trials are small and measured insulin action and immune cells, not the liver. The metabolic audit shows which markers are worth tracking instead.

Does milk thistle lower liver enzymes?

Modestly, in some people. A synthesis of 55 studies found drops in AST and ALT in fatty liver and viral hepatitis, but no change in alkaline phosphatase and no effect at a body mass index of 30 or above. Its apparent mortality benefit lost statistical certainty when only high-quality trials were counted. Safety was consistently comparable to placebo. Why a normal GGT result is not the same as a healthy liver adds context.

Do liver cleanses really flush out gallstones?

The best-studied case says no. The green objects passed after an olive oil and citrus cleanse were mostly fatty acids, with none of the cholesterol, bilirubin or calcium in real gallstones, and they could be recreated on a lab bench. The woman who passed them still had her stones. Gallstone disease also travels with fatty liver and metabolic syndrome. Metabolic inflammation is the terrain behind both.

Does bile change the gut microbiome?

Yes, in the direction you would predict. In cirrhosis, where bile delivery falls, secondary bile acids dropped and the bacterial families that transform bile acids declined, while Enterobacteriaceae rose. Specific organisms tracked specific bile acids. That study was cross-sectional, so it cannot say which changed first, and a stool readout is not what the small bowel experienced. What a stool microbiome report can and cannot tell you explains that limit.

Is cascara sagrada safe to use long term?

Nobody knows, and that is the problem. Cascara lost over-the-counter laxative status in 2002 because the requested data on genetic damage and cancer were never submitted. That is a gap in evidence, not a finding of harm, but it leaves a daily-use product without a safety file. Any laxative plan belongs in a conversation with your physician. How some pain medications stall the gut covers a common reason people reach for one.

Sources

1. Sies, C. W., & Brooker, J. (2005). Could these be gallstones?. Lancet, 365(9468), 1388. https://doi.org/10.1016/S0140-6736(05)66373-8
2. Rudic, J. S., Poropat, G., Krstic, M. N., Bjelakovic, G., & Gluud, C. (2012). Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database of Systematic Reviews, 12(12), CD000551. https://doi.org/10.1002/14651858.CD000551.pub3
3. Kars, M., Yang, L., Gregor, M. F., Mohammed, B. S., Pietka, T. A., Finck, B. N., Patterson, B. W., Horton, J. D., Mittendorfer, B., Hotamisligil, G. S., & Klein, S. (2010). Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes, 59(8), 1899-1905. https://doi.org/10.2337/db10-0308
4. Ladakis, D. C., Harrison, K. L., Smith, M. D., Solem, K., Gadani, S., Jank, L., Hwang, S., Farhadi, F., Dewey, B. E., Fitzgerald, K. C., Sotirchos, E. S., Saidha, S., Calabresi, P. A., & Bhargava, P. (2025). Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease. Med, 6(3), 100522. https://doi.org/10.1016/j.medj.2024.09.011
5. Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., Abergel, A., Debette-Gratien, M., Larrey, D., Roux, O., Bronowicki, J. P., Boursier, J., de Ledinghen, V., Heurgue-Berlot, A., Nguyen-Khac, E., … Poupon, R. (2018). A placebo-controlled trial of bezafibrate in primary biliary cholangitis. New England Journal of Medicine, 378(23), 2171-2181. https://doi.org/10.1056/NEJMoa1714519
6. Rambaldi, A., Jacobs, B. P., & Gluud, C. (2007). Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database of Systematic Reviews, 2007(4), CD003620. https://doi.org/10.1002/14651858.CD003620.pub3
7. Fried, M. W., Navarro, V. J., Afdhal, N., Belle, S. H., Wahed, A. S., Hawke, R. L., Doo, E., Meyers, C. M., & Reddy, K. R. (2012). Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA, 308(3), 274-282. https://doi.org/10.1001/jama.2012.8265
8. Shahsavari, K., Ardekani, S. S., Ardekani, M. R. S., Esfahani, M. M., Kazemizadeh, H., Jamialahmadi, T., Iranshahi, M., Khanavi, M., & Hasanpour, M. (2025). Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury. BMC Complementary Medicine and Therapies, 25(1), 134. https://doi.org/10.1186/s12906-025-04886-y
9. Kakiyama, G., Pandak, W. M., Gillevet, P. M., Hylemon, P. B., Heuman, D. M., Daita, K., Takei, H., Muto, A., Nittono, H., Ridlon, J. M., White, M. B., Noble, N. A., Monteith, P., Fuchs, M., Thacker, L. R., Sikaroodi, M., & Bajaj, J. S. (2013). Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. Journal of Hepatology, 58(5), 949-955. https://doi.org/10.1016/j.jhep.2013.01.003
10. U.S. Food and Drug Administration, Department of Health and Human Services (2002). Status of certain additional over-the-counter drug category II and III active ingredients. Final rule. Federal Register, 67(90), 31125-31127 (FR Doc No: 02-11510). https://www.govinfo.gov/content/pkg/FR-2002-05-09/html/02-11510.htm

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 28 of The Angry Gut by Dr. Padda and Ami Michelle Grimes. Last reviewed September 2026.